Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial

被引:84
|
作者
Sigal, G. B. [1 ]
Segal, M. R. [2 ]
Mathew, A. [1 ]
Jarlsberg, L. [2 ]
Wang, M. [1 ]
Barbero, S. [1 ]
Small, N. [1 ]
Haynesworth, K. [1 ]
Davis, J. L. [3 ,4 ]
Weiner, M. [5 ]
Whitworth, W. C. [6 ]
Jacobs, J. [7 ]
Schorey, J. [8 ]
Lewinsohn, D. M. [9 ]
Nahid, P. [2 ]
机构
[1] Meso Scale Diagnost LLC, Rockville, MD USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Yale Sch Publ Hlth, New Haven, CT USA
[4] Yale Sch Med, New Haven, CT USA
[5] San Antonio VA Med Ctr, San Antonio, TX USA
[6] Ctr Dis Control & Prevent, Atlanta, GA USA
[7] Pacific Northwest Natl Lab, Richland, WA USA
[8] Univ Notre Dame, Notre Dame, IN 46556 USA
[9] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源
EBIOMEDICINE | 2017年 / 25卷
基金
美国国家卫生研究院;
关键词
Host immune response; Tuberculosis; Biomarkers; Clinical trials; ACTIVE PULMONARY TUBERCULOSIS; INTENSIVE PHASE TREATMENT; TREATMENT RESPONSE; INTERSTITIAL PNEUMONIA; INDIVIDUAL PATIENT; ALPHA-DEFENSINS; DISEASE; SERUM; INFECTION; REGIMENS;
D O I
10.1016/j.ebiom.2017.10.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
More efficacious treatment regimens are needed for tuberculosis, however, drug development is impeded by a lack of reliable biomarkers of disease severity and of treatment effect. We conducted a directed screen of host biomarkers in participants enrolled in a tuberculosis clinical trial to address this need. Serum samples from 319 protocol-correct, culture-confirmed pulmonary tuberculosis patients treated under direct observation as part of an international, phase 2 trial were screened for 70 markers of infection, inflammation, and metabolism. Biomarker assays were specifically developed for this study and quantified using a novel, multiplexed electrochemiluminescence assay. We evaluated the association of biomarkers with baseline characteristics, as well as with detailed microbiologic data, using Bonferroni-adjusted, linear regression models. Across numerous analyses, seven proteins, SAA1, PCT, IL-1 beta, IL-6, CRP, PTX-3 and MMP-8, showed recurring strong associations with markers of baseline disease severity, smear grade and cavitation; were strongly modulated by tuberculosis treatment; and had responses that were greater for patients who culture-converted at 8 weeks. With treatment, all proteins decreased, except for osteocalcin, MCP-1 and MCP-4, which significantly increased. Several previously reported putative tuberculosis-associated biomarkers (HOMX1, neopterin, and cathelicidin) were not significantly associated with treatment response. In conclusion, across a geographically diverse and large population of tuberculosis patients enrolled in a clinical trial, several previously reported putative biomarkers were not significantly associated with treatment response, however, seven proteins had recurring strong associations with baseline radiographic and microbiologic measures of disease severity, as well as with early treatment response, deserving additional study. (C) 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license.
引用
收藏
页码:112 / 121
页数:10
相关论文
共 50 条
  • [1] Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis
    Jayakumar, A.
    Vittinghoff, E.
    Segal, M. R.
    MacKenzie, W. R.
    Johnson, J. L.
    Gitta, P.
    Saukkonen, J.
    Anderson, J.
    Weiner, M.
    Engle, M.
    Yoon, C.
    Kato-Maeda, M.
    Nahid, P.
    TUBERCULOSIS, 2015, 95 (04) : 415 - 420
  • [2] Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial
    Dekkers, Bart G. J.
    Kerstjens, Huib A. M.
    Breisnes, Helene W.
    Leeming, Diana J.
    Anthony, Richard M.
    Frijlink, Henderik W.
    van der Werf, Tjip S.
    Kosterink, Jos G. W.
    Alffenaar, Jan-Willem C.
    Akkerman, Onno W.
    JOURNAL OF INFECTIOUS DISEASES, 2025,
  • [3] Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial
    Wallis, Robert S.
    Ginindza, Sibuse
    Beattie, Trevor
    Arjun, Nishanee
    Likoti, Morongwe
    Sebe, Modulakgotla
    Edward, Vinodh A.
    Rassool, Mohammed
    Ahmed, Khatija
    Fielding, Katherine
    Ahidjo, Bintou A.
    Vangu, Mboyo D. T.
    Churchyard, Gavin
    PLOS ONE, 2022, 17 (02):
  • [4] Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint
    Michiels, Stefan
    Potthoff, Richard F.
    George, Stephen L.
    STATISTICS IN MEDICINE, 2011, 30 (13) : 1502 - 1518
  • [5] Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial
    Marjani, Majid
    Baghaei, Parvaneh
    Dizaji, Mehdi Kazempour
    Bayani, Pegah Gorji
    Fahimi, Fanak
    Tabarsi, Payam
    Velayati, Ali Akbar
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 15 (01): : 247 - 252
  • [6] Effect of Screen Time on Recovery From Concussion A Randomized Clinical Trial
    Macnow, Theodore
    Curran, Tess
    Tolliday, Courtney
    Martin, Kirsti
    McCarthy, Madeline
    Ayturk, Didem
    Babu, Kavita M.
    Mannix, Rebekah
    JAMA PEDIATRICS, 2021, 175 (11) : 1124 - 1131
  • [7] Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment
    Jacobs, Ruschca
    Tshehla, Enock
    Malherbe, Stephanus
    Kriel, Magdalena
    Loxton, Andre G.
    Stanley, Kim
    van der Spuy, Gian
    Walzl, Gerhard
    Chegou, Novel N.
    CYTOKINE, 2016, 81 : 50 - 56
  • [8] Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
    Wallis, Robert S.
    Maeurer, Markus
    Mwaba, Peter
    Chakaya, Jeremiah
    Rustomjee, Roxana
    Migliori, Giovanni Battista
    Marais, Ben
    Schito, Marco
    Churchyard, Gavin
    Swaminathan, Soumya
    Hoelscher, Michael
    Zumla, Alimuddin
    LANCET INFECTIOUS DISEASES, 2016, 16 (04): : E34 - E46
  • [9] Effect of probiotics in the treatment of NASH: A randomized clinical trial
    Port, Gabriela
    Tovo, Cristiane
    Fernandes, Sabrina
    Peres, Alessandra
    Dornelles, Gilson
    Pinto, Giselle
    Houde, Vanessa
    Varin, Thibault
    Pilon, Genevieve
    Marette, Andre
    Buss, Caroline
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E517 - E517
  • [10] Treatment of periodontitis ameliorates the severity and extent of psoriasis-A randomized clinical trial
    Marruganti, Crystal
    Romandini, Mario
    Gaeta, Carlo
    Trovato, Emanuele
    Cinotti, Elisa
    Rubegni, Pietro
    D'Aiuto, Francesco
    Grandini, Simone
    JOURNAL OF PERIODONTAL RESEARCH, 2025, 60 (02) : 134 - 143